预弯开窗支架行0-1区TEVAR的中期结果
本研究评估第二代预弯开窗支架治疗主动脉弓疾病的中期效果,为非随机干预性多中心临床试验的一部分,纳入205例近端锚定区为0或1区的患者。初次成功率为94%,技术成功率为91%,5年总体生存率为71%,主动脉相关无死亡生存率5年为97.8%。
要点
- 第二代预弯开窗支架行TEVAR治疗主动脉弓疾病中期结果良好。
- 5年总体生存率71%,主动脉相关无死亡生存率97.8%。
- 再次手术最常见原因为Ia型内漏(5%)。
核心结论
- 预弯开窗支架对主动脉弓有良好顺应性,使0区锚定成为可能,中期结果表明该方法是主动脉弓疾病的有价值腔内治疗选择。
研究设计与样本
- 非随机干预性研究,为2010至2011年开展的多中心临床试验的一部分,评估第二代预弯开窗支架治疗主动脉弓疾病的有效性。
- 纳入205例近端锚定区为0或1区、接受该支架治疗的患者,评估术后第五年收集的中期生存、再次手术和并发症数据。
主要发现
- 初期成功率为94%,技术成功率为91%。
- 97%的患者使用0区锚定。
- 院内死亡率3%;5年总体生存率71%。
- 术后1年和5年主动脉相关无死亡生存率分别为99.5%和97.8%。
- 术后1年和5年动脉瘤相关无事件生存率分别为86.8%和77.1%;5年无再次手术生存率86.6%。
关键数值与推荐
- 再次手术最常见原因为Ia型内漏(5%),其次为II型内漏(2%)。
- 脑梗死、装置移位、脊髓缺血和主动脉上分支狭窄的发生率分别为6%、1%、1%和1%。
临床怎么用
- 对于主动脉弓疾病,使用第二代预弯开窗支架行TEVAR可实现0区锚定,中期结果支持其作为有价值的腔内治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Thoracic endovascular aortic repair (TEVAR) for the treatment of aortic arch disease remains challenging due to certain anatomical and haemodynamic features. The purpose of this study was to evaluate the midterm results of TEVAR with a second-generation fenestrated endograft for aortic arch disease. METHODS: This non-randomized, interventional study was part of a multicentre clinical trial conducted between 2010 and 2011 and was designed to assess the effectiveness of a second-generation precurved fenestrated endograft for aortic arch disease. Midterm data collected during the fifth postoperative year from 205 patients treated with this endograft with the proximal landing of zone 0 or 1 were assessed regarding survival, reoperation and complications. RESULTS: The initial and technical success rates were 94% and 91%, respectively. Ninety-seven percent of patients were treated using zone 0. The rate of in-hospital deaths was 3%. Overall survival was 71% at 5 years; thoracic aorta-related death-free survival rates at 1 and 5 years after surgery were 99.5% and 97.8%, respectively. Aneurysm-related event-free survival rates at 1 and 5 years after surgery were 86.8% and 77.1%, respectively. Reoperation-free survival rates at 5 years were 86.6%. The most frequent reason for reoperation was type Ia endoleak (5%), followed by type II endoleak (2%). Incidences of cerebral infarction, device migration, spinal cord ischaemia and supra-aortic branch stenosis were 6%, 1%, 1% and 1%, respectively. CONCLUSIONS: The precurved fenestrated endograft provided appropriate conformability to the aortic arch and made zone 0 landing possible with simplified, less-invasive manipulations. The midterm results of TEVAR with this endograft suggest this method is a valuable endovascular treatment option for aortic arch disease. CLINICAL TRIAL REGISTRATION NUMBER: UMIN000007213.
引用
- Furuta A, Azuma T, Yokoi Y, et al. The midterm results of thoracic endovascular aortic repair with a precurved fenestrated endograft in zone 0-1. Eur J Cardiothorac Surg. 2020. PMID: 32623460. doi:10.1093/ejcts/ezaa165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。